Due to the ubiquitous and vital expression of the PI3K pathway in a range of cells, the use of many pan-PI3K inhibitors has been limited by toxicity, particularly gastrointestinal, hepatic and cutaneous, and hyperglycaemia, and many have also shown limited anticancer efficacy [56]. This evidence concerns the gene PIK3CA and Hyperglycemia.